Clinical Trial Update: A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety of INT2104 infusions in adults with B-cell cancers, including B-cell non-Hodgkin lymphoma and precursor B-cell acute lymphoblast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Precursor B-cell Acute Lymphoblastic Leukemia Lymphoma

Drugs mentioned

• INT2104 (INT2104)

Snippet

Sponsor: Kite, A Gilead Company | Conditions: Lymphomas Non-Hodgkin's B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING